| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03:54 | Pro Research: Wall Street dives into Regeneron's robust prospects | 3 | Investing.com | ||
| Fr | Regeneron Pharmaceuticals, Inc. (REGN) Q1 2024 Earnings Call Transcript | 2 | Insider Monkey | ||
| Do | Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation | 4 | Benzinga.com | ||
| Do | Regeneron reveals potential delay for Dupixent in COPD, stagnant sales for Eylea | 4 | FiercePharma | ||
| Do | Regeneron, Lilly grapple with clinical endpoints as obesity space moves to improving weight loss | 9 | FierceBiotech | ||
| Do | Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years | 5 | Benzinga.com | ||
| Do | Regeneron falls after Q1 miss; announces $3B share buybacks | 11 | Seeking Alpha | ||
| Do | Regeneron Pharmaceuticals Q1 Profit Decreases, misses estimates | 208 | AFX News | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals (REGN) reported a profit for first quarter that decreased from the same period last year and missed the Street estimates.The company's earnings... ► Artikel lesen | |
| Do | Regeneron misses earnings, revenue expectations | 3 | Investing.com | ||
| Do | Regeneron Earnings Miss; Biotech Giant's Stock Falls | 5 | Investor's Business Daily | ||
| Do | REGENERON PHARMACEUTICALS, INC. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| Do | Regeneron misses profit estimates on weaker Eylea and Dupixent sales | 4 | Reuters | ||
| Do | REGENERON PHARMACEUTICALS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| Do | Regeneron Pharma earnings missed by $0.64, revenue fell short of estimates | 3 | Investing.com | ||
| Do | Regeneron Pharma: EPS verfehlt Schätzungen um 0,64 $ - Umsatz schlechter als erwartet | 5 | Investing.com Deutsch | ||
| Do | Regeneron Pharmaceuticals misses top-line and bottom-line estimates; updates FY24 outlook | 4 | Seeking Alpha | ||
| Do | Regeneron Pharmaceuticals, Inc.: Regeneron Reports First Quarter 2024 Financial and Operating Results | 45 | GlobeNewswire (Europe) | First quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding RonapreveTM(a)(b), revenues increased 7%First quarter 2024 Dupixent® global net sales (recorded by Sanofi)... ► Artikel lesen | |
| Mi | Roche's VABYSMO has successful Q1 sales despite Regeneron and Bayer's EYLEA HD launch | 74 | Pharmaceutical Technology | ||
| Di | Regeneron Pharmaceuticals Inc expected to post earnings of $10.10 a share - Earnings Preview | 4 | Reuters | ||
| Di | Enlaza gets JP Morgan, Regeneron backing for covalent biologics | 4 | BioPharma Dive |
Seite:
1 2 3 4 5 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 2.665 |
| NEL | 1.568 |
| APPLE | 1.462 |
| BAYER | 1.372 |
| BYD | 1.369 |
| SUPER MICRO COMPUTER | 1.274 |
| DEUTSCHE BANK | 1.178 |
| TUI | 1.145 |
| NVIDIA | 1.120 |
| PLUG POWER | 985 |
| TESLA | 941 |
| DAIMLER TRUCK | 899 |
| MERCEDES-BENZ | 861 |
| RWE | 834 |
| RHEINMETALL | 823 |
| AURUBIS | 766 |
| RENK GROUP | 739 |
| DEUTSCHE LUFTHANSA | 727 |
| VOLKSWAGEN | 722 |
| COMMERZBANK | 717 |
| AMAZON | 690 |
| SIEMENS ENERGY | 657 |
| AIXTRON SE | 624 |
| SIXT SE VZ | 621 |
| NORDEX | 570 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
